Reflections from RSNA 2025: AI is everywhere, but are we solving the right problems?
RSNA 2025 highlighted a crowded AI landscape—but also the growing complexity of multi-site imaging trials. Learn why scanner variability, protocol...
RSNA 2025 highlighted a crowded AI landscape—but also the growing complexity of multi-site imaging trials. Learn why scanner variability, protocol...
Take a look ahead at our predicted trends for neuroscience in 2025 - where technology, neuroplasticity, and neuroethics are reshaping the way we...
Is your imaging facility drowning in data? Spot 5 warning signs of poor imaging data management and discover solutions to transform chaos into...
Manual reviews slow studies and add risk. Learn how QMENTA automates imaging review and QC with AI workflows that adapt to any protocol.
AI pioneer Dr. John E. Kelly III shares insights on building trust, improving data, and driving progress in AI-enabled neurological trials.
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and...